We are on a mission to address the most challenging and unaddressed diseases impacting humankind.
PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need for combination therapies.
We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform developed by VeriSIM Life, to accelerate our drug development by bridging the translational gap between preclinical and clinical phases.
Currently, we have 2 drug assets in our pipeline for PAH and IPF. We have successfully accomplished the proof-of-concept preclinical studies with key disease-reversal data. We are working hand-in-hand with a world-class strategic advisory board and clinical and manufacturing partners to finish IND-enabling studies to further our developmental roadmap for regulatory approvals.
PT001 has been granted Orphan Drug Designation by the U.S. Food & Drug Administration: June 7, 2021.
TEAM & ADVISORY BOARD